Ashutosh Upadhyay retweeted
Chandrayaan-3 Mission:
Here are the first observations from the ChaSTE payload onboard Vikram Lander.
ChaSTE (Chandra's Surface Thermophysical Experiment) measures the temperature profile of the lunar topsoil around the pole, to understand the thermal behaviour of the moon's surface. It has a temperature probe equipped with a controlled penetration mechanism capable of reaching a depth of 10 cm beneath the surface. The probe is fitted with 10 individual temperature sensors.
The presented graph illustrates the temperature variations of the lunar surface/near-surface at various depths, as recorded during the probe's penetration. This is the first such profile for the lunar south pole. Detailed observations are underway.
The payload is developed by a team led by the Space Physics Laboratory (SPL), VSSC vssc.gov.in/spl.htmlin collaboration with PRL, Ahmedabad prl.res.in/prl-eng/
Ashutosh Upadhyay retweeted
OneCell Dx will be at #AACR2023 showcasing the groundbreaking research as 3 posters in the event. Do visit us for the latest findings. We can't wait to share them with the scientific community!
#CancerResearch #precisiononcology @KhandareJayant @aravasudevan @Ashucsu @GowharShafi
Ashutosh Upadhyay retweeted
On World Cancer Day, we come together as One world to raise awareness and fight against this devastating disease. Let us join hands to close the care gap. We are one world to fight #cancer One cell at a time #worldcancerday #oncology #cancerawareness #cancerresearch #Genomics
Ashutosh Upadhyay retweeted
3 key takeaways from talk of @UmbertoMalapel1:
1. Consensus needed for standardized classification, annotation, interpretation & reporting
2. #Cancer is a dynamic disease & #NGS must provide real time snapshot of the tumor biology
3. #LiquidBiopsy transforming cancer diagnosis
Ashutosh Upadhyay retweeted
Join us as we host Dr Ashwin Dalal, Head, Diagnostics Division, @DBT_CDFD and discuss #principles of #interpretation of #variants detected in #NGS
𝗠𝗮𝗿𝗰𝗵 𝟯𝟭 | 𝟯:𝟯𝟬 𝗽𝗺 𝗜𝗦𝗧
Here's the link: lnkd.in/gCNTWJ6Y
#geneticdisease #exomesequencing #genomics
Ashutosh Upadhyay retweeted
NEXT HORIZONS IN #CANCER | The time is ripe to leverage latest advances in #genomic and #DNA #technology to personalize #cancer care & institutionalize early detection, writes Dr Ashutosh Upadhyay (Product Manager, Clinical Genomics, @PremasLifeSc )
voiceofhealthcare.org/blogde…
Ashutosh Upadhyay retweeted
Join us as Dr Pratibha Kale, Associate Professor at @ilbs_delhi will discuss the importance of assessing the presence of Neutralizing Antibodies in #convalescentplasma used therapeutically in #covid19 #patients.
Date: 16/10/2020, 4 PM IST
Register Here: lnkd.in/eu8J2Yf
Ashutosh Upadhyay retweeted
India pushes bold ‘one nation, one subscription’ journal-access plan nature.com/articles/d41586-0…
Ashutosh Upadhyay retweeted
Register today for the 10x Genomics Innovation Lab, a virtual panel discussion at APAC friendly times on October 15. Explore how recent advances in #singlecell methodology provide deeper insights into vaccine research and antibody discovery. bit.ly/3iC4oCs
Ashutosh Upadhyay retweeted
Mark your calendars! Join us on Thursday, September 24th, as Dr. Marilyn Li presents on NTRK fusions in childhood tumors #NTRK #solidtumor @GenomeWeb hubs.li/H0wvdsS0
Ashutosh Upadhyay retweeted
@DBTIndia has established the National Genomics Core (NGC) with its hub in @FollowDbtNibmg & centres in @CDFD36684672 & @univofalld . NGC provides consultancy & services to academia & industry, using NGC facilities for human & bacterial meta-genomics @drharshvardhan @RenuSwarup
Ashutosh Upadhyay retweeted
Learn more about implementing #oncology #NGS workflows in your laboratory, from best practices at the bench to options for #clinicalreporting. @gerald_goh @illumina #precisionmedicine #sequencing
Date: 18th June, 11am
Register: ilmnmkt.illumina.com/2016004…
Ashutosh Upadhyay retweeted
#Covid19 patients #genomic data should be aligned to #popseq initiatives which will give a rich #repository for info on #infection susceptibility, pertinent to India, just like its happening in UK - bit.ly/2YZmYNZ @RenuSwarup @ICMRDELHI @CSIR_IND @IGIBSocial @ccmb_csir
Ashutosh Upadhyay retweeted
#LearnAtHome with us to understand the need for better, accurate and efficient #vaccine characterization techniques for characterizing #proteins, Virus-Like Particles, #vaccines, and #AAV.
Date: May 12th, 2020 - 9:30 AM IST
Register here: lnkd.in/gcj_eGk
@unchainedlabs
Ashutosh Upadhyay retweeted
ICMR has rapidly expanded testing for COVID-19 effectively! For more details visit: icmr.nic.in #ICMRFIGHTSCOVID19 #IndiaFightsCorona
Ashutosh Upadhyay retweeted
1000 SARS Cov-2 genomes will be sequenced from the clinical samples to understand the evolving molecular phylogeny of the virus and the emerging mutations in the viral RNA as well as identify the host genetic variations. @drharshvardhan @RenuSwarup @BIRAC_2012
Ashutosh Upadhyay retweeted
180000 #Covid_19 #rtpcr tests in one months per machine.#TestingTestingTesting #COVID2019india #icmrfightscovid19
The new real-time PCR #COVID19 test from @OMRF and @OUHSC_research, run on the Biomark HD system, combines scalability with the high capacity (180,000 tests over 90 days) needed to test and screen patients, high-risk individuals and first responders.
genomeweb.com/pcr/oklahoma-i…
Ashutosh Upadhyay retweeted
Thanks to @FollowCII @NASSCOMfdn @GCNIndia @ficci_india for supporting #Covid_19 #research.
@PrinSciAdvOff will now #focus on facilitating #DrugDiscovery, #vaccination, #sequencing, #testing & #reagents. Any #support to the research #institutes will be appreciated!
Ashutosh Upadhyay retweeted
#Funding opportunities for battling #COVID19, this new pandemic requires new #innovative approaches. We are offering products from @fluidigm #biomarkHD #cytof @ProteinSimple #Ella & many more. Do reach out to us if you require more info about the products. WE ARE READY TO HELP!!
Call for Fast Track Funding Opportunities for Translational
Immunology Approaches to COVID-19. More information icmr.nic.in/sites/default/fi…



































